Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials

Annals of Oncology

Volumn 28, Issue 3, 2017, Pages 562-568

  Seligmann, J F ^a   Fisher, D ^b   Smith, C G ^c   Richman, S D ^a   Elliott, F ^a   Brown, S ^a   Adams, R ^c   Maughan, T ^d   Quirke, P ^a   Cheadle, J ^c   Seymour, M ^a   Middleton, Gary ^e  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

BRAF mutant; Chemotherapy; Colorectal cancer; Prognosis

Indexed keywords

B RAF KINASE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; CAMPTOTHECIN; PLATINUM COMPLEX;

ADULT; ADVANCED COLORECTAL CANCER; AGED; ARTICLE; B RAF KINASE GENE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL HETEROGENEITY; COLORECTAL CANCER; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POST PROGRESSION SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; CANCER STAGING; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; TREATMENT OUTCOME;

EID: 85018261805     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw645     Document Type: Article

References (23)

1. Morris V, Overman MJ, Jiang ZQ et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAFmutated colorectal cancer. Clin Colorectal Cancer 2014; 13(3): 164-171.
2. Tol J, Nagtegaal ID, Punt CJ et al. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-99.
3. Cremolini C, Loupakis F, Antoniotti C et al. Folfoxiri plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16(13): 1306-1315.
4. Venderbosch S, Nagtegaal ID, Maughan TS et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014; 20: 5322-5330.
5. Price TJ, Hardingham JE, Lee CK et al. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol 2011; 29: 2675-2682.
6. Rowland A, Dias MM, Wiese MD et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015; 112(12): 1888-1894.
7. Kopetz SD, Desai J, Chan E et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 2010; 28(15s): Abstr.3534.
8. Corcoran RB, Atreya CE, Falchook GS et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol 2015; 33(34): 4023-4031.
9. Clancy C, Burke JP, Kalady MF et al. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Colorectal Dis 2013; 15: e711-e718.
10. Tran B, Kopetz S, Tie J et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117(20): 4623-4632.
11. Loupakis F, Yang D, Yau L et al. Primary tumour location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015; 107(3): dju427.
12. Franko J, Shi Q, Goldman CD et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2011; 30(3): 263-267.
13. Seymour MT, Maughan TS, Ledermann JA et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143-152.
14. Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114.
15. Adams RA, Meade AM, Seymour MT et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011; 12: 642-653.
16. Seymour MT, Brown SR, Middleton G et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013; 14: 749-759.
17. Middleton G, Brown S, Lowe C et al. A randomised phase III trial of the pharmacokinetic bimodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in Colorectal cancer therapy trial (PICCOLO). Eur J Cancer 2013; 49: 3507-3516.
18. Richman SD, Seymour MT, Chambers P et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27: 5931-5937.
19. Smith CG, Fisher D, Claes B et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy +/-cetuximab. Clin Cancer Res 2013; 19: 4104-4113.
20. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
21. Andre T, de Gramont A, Vernery D et al. Adjuvant Fluoruracil, Leucovorin, and Oxaliplatin in Stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC Study.
22. Corcoran RB, Andre T, Yoshino T et al. Efficacy and circulating tumour DNA analysis of the BRAF inhibitor dabrafanib, MEK inhibitor trametinib and anti-EGFR antibody panitumumab in patients with BRAF V600E-mutated metastatic colorectal cancer. Ann Oncol 2016; 34(Suppl): Abstr. 455.
23. Barras D, Missiaglia E, Wirapati P et al. BRAF V600E mutant colorectal cancer subtypes based on gene expression. Clin Cancer Res, doi:10.1158/ 1078-0432.CCR-16-0140.